R&D News | pharmaphorum

News

Sage Therapeutics' chief executive Barry Greene

Sage drops dalzanemdor for Parkinson’s after trial flop

Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed

News

Trials set up filing for Lilly’s tirzepatide in sleep apnoea

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.

News

MaaT Pharma's chief executive and co-founder Hervé Affagard

MaaT microbiota drug shows survival advantage in GvHD

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access pro

News

GSK reveals data on novel gonorrhoea drug gepotidacin

GSK has unveiled the data for its novel antibiotic gepotidacin as a treatment for gonorrhoea, putting the drug on track to become an important therapy for people with resistant forms

News

Intra-Cellular sets up $500m offer on Caplyta depression win

Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a p

News

Boehringer says R&D pipeline is the best in its long history

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that

Sage drops dalzanemdor for Parkinson’s after trial flop

Trials set up filing for Lilly’s tirzepatide in sleep apnoea

MaaT microbiota drug shows survival advantage in GvHD

GSK reveals data on novel gonorrhoea drug gepotidacin

Intra-Cellular sets up $500m offer on Caplyta depression win

Boehringer says R&D pipeline is the best in its long history

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks